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IKKb-dependent NF-kB activation plays a key
role in innate immunity and inflammation, and
inhibition of IKKb has been considered as
a likely anti-inflammatory therapy. Surprisingly,
however, mice with a targeted IKKb deletion in
myeloid cells are more susceptible to endo-
toxin-induced shock than control mice. In-
creased endotoxin susceptibility is associated
with elevated plasma IL-1b as a result of in-
creased pro-IL-1b processing, which was also
seen upon bacterial infection. In macrophages
enhanced pro-IL-1b processing depends on
caspase-1, whose activation is inhibited by
NF-kB-dependent gene products. In neutro-
phils, however, IL-1b secretion is caspase-1 in-
dependent and depends on serine proteases,
whose activity is also inhibited by NF-kB gene
products. Prolonged pharmacologic inhibition
of IKKb also augments IL-1b secretion upon
endotoxin challenge. These results unravel an
unanticipated role for IKKb-dependent NF-kB
signaling in the negative control of IL-1b pro-
duction and highlight potential complications
of long-term IKKb inhibition.
INTRODUCTION
Acute inflammation resulting in septic shock and multior-
gan dysfunction (MOD) is a common cause of death in918 Cell 130, 918–931, September 7, 2007 ª2007 Elsevier Inc.intensive care units (Hotchkiss and Karl, 2003). Sepsis is
a systemic inflammatory response occurring after mas-
sive bacterial infection or severe trauma, and in addition
to septic shock and MOD, it can cause other complica-
tions such as adult respiratory distress syndrome
(ARDS) (Cohen, 2002). Despite advances in antimicrobial
treatment and supportive therapy, mortality remains high
in septic patients (Hotchkiss and Karl, 2003).
Duringmicrobial infections, pathogen-associatedmole-
cular patterns (PAMPs) are recognized by the host
defense system, whichmounts a protective response (Co-
hen, 2002). A similar response is triggered by endogenous
mediators, which are released by necrotic cells during
trauma (Karin et al., 2006). The initial inflammatory reac-
tion is amplified, and once amplification becomes exces-
sive, shock and MOD can occur (Cohen, 2002). Myeloid
cells are critical for PAMP recognition and initiation and
amplification of the inflammatory cascade, mainly through
transcriptional regulation of genes encoding key inflam-
matory mediators, such as the cytokines TNF-a and IL-
1b (Dinarello, 1997). In endotoxic shock TNF-a and IL-1b
are released rapidly (after 30–90 min of onset) (Dinarello,
1997) and activate a secondary inflammatory cascade,
dependent on transcription factor NF-kB (Ghosh and
Karin, 2002). More recently, a novel system termed the in-
flammasome, involved in posttranscriptional control of in-
flammation and innate immunity, has been described
(Martinon and Tschopp, 2004). The inflammasome system
is based on ligand-dependent activation of caspase-1
(also termed interleukin-1b-converting enzyme [ICE]) and
other proinflammatory caspases that carry out process-
ing of cytoplasmatic pro-IL-1b and pro-IL-18 (Martinon
and Tschopp, 2004). It is presently unclear whether the
NF-kB and inflammasome systems interact, other than
through the synthesis of pro-IL-1b, which is transcription-
ally regulated by NF-kB.
One way to inhibit NF-kB activation is to use small-
molecule inhibitors of IKKb (Karin et al., 2004), one of the
two catalytic subunits of the IKK complex, which is critical
for NF-kB activation during acute inflammation (Chen
et al., 2003). IKK/NF-kB blockade has been proposed as
a therapeutic modality for preventing mortality in septic
shock and MOD (Zingarelli, 2005). However, there are
certain potential complications associated with this
approach, such as a marked increase in susceptibility to
apoptosis (Chen et al., 2003; Kisseleva et al., 2006) or
perhaps a failure to induce negative regulators, such as
A20 (Lee et al., 2000). In addition, NF-kB plays a central
role in activation of the host defense system (Li and
Verma, 2002), and therefore IKK inhibition can increase
susceptibility to infections. In fact, certain pathogens,
such as Yersinia pestis, inhibit IKK activation to evade
host defense (Orth et al., 2000).
To examine whether IKKb inhibition might prevent sep-
tic shock, we have conditionally disrupted the Ikkb gene in
myeloid cells, and subjected the resultant mice, termed
IkkbDmye, to endotoxin challenge. Surprisingly, IkkbDmye
miceweremore susceptible to endotoxin-inducedmortal-
ity and showed significantly increased levels of circulating
IL-1b, due to enhanced pro-IL-1b processing. Enhanced
IL-1b secretion in myeloid IKKb-deficient mice was also
seen upon bacterial infection. Prolonged pharmacological
inhibition of IKKb, which interferes with NF-kBactivation in
the whole animal, also increased lipopolysaccharide
(LPS)-inducedmortality and plasma IL-1b. Thus, our stud-
ies, which uncovered an unexpected role for IKKb-driven
NF-kB in the negative control of IL-1b secretion, strongly
suggest that the therapeutic use of IKKb inhibitors may re-
sult in unintended effects on the host response. Enhanced
secretion of IL-1b and similarly regulated cytokines by NF-
kB-deficient myeloid cells may have evolved as a protec-
tive strategy that provides innate immunity to microbes
that produce NF-kB inhibitors.
RESULTS
Mice Lacking Myeloid IKKb Are Hypersusceptible
to Endotoxic Shock
To examine the impact of myeloid-specific IKKb inhibition
on endotoxic shock, we crossed LysM-Cre mice (Clausen
et al., 1999) to ‘‘floxed’’ Ikkb mice to delete Ikkb alleles in
macrophages and neutrophils. The resulting mice, termed
IkkbDmye, lack IKKb protein and kinase activity, resulting in
defective NF-kB activation only in myeloid cells, with no
overt changes in the overall histology of lymphoid organs
and other sites rich in myeloid cells, such as the gastroin-
testinal tract and liver (see Figure S1 in the Supplemental
Data, available with this article online) (Arkan et al., 2005;
Greten et al., 2004). IkkbDmye and IkkbF/F control mice
were intraperitonealy (i.p.) challenged with a high dose
of Escherichia coli LPS (30 mg/kg) and monitored for sur-
vival. Unexpectedly, all IkkbDmye mice died within 36 hr,Cwhereas 50% of IkkbF/F controls survived for >72 hr
(Figure 1A). Enhanced LPS toxicity in IkkbDmyemice corre-
lated with both a marked increase in plasma IL-1b levels
within the first 2 hr (Figure 1B) and modestly elevated
plasma TNF-a (Figure 1C), whereas there was no differ-
ence in plasma IL-6 levels (Figure 1D). To address whether
increased IL-1b secretion was restricted to challenge with
the TLR4 agonist LPS or whether this was a more general
phenomenon, we also injected mice of either genotype
with the TLR9 agonist CpG-ODN or Listeria monocyto-
genes. In both cases IkkbDmye mice showed increased
plasma IL-1b levels relative to those of IkkbF/F controls
(Figure S2), suggesting a general mechanism.
To determine whether enhanced LPS toxicity in
IkkbDmye mice was due to elevated IL-1b, we treated
IkkbDmye mice and IkkbF/F controls with recombinant IL-1
receptor (IL-1R) antagonist (IL-1ra) (Anakinra) to block
IL-1R activation. IL-1ra completely protected IkkbDmye
(and IkkbF/F) mice against LPS-induced mortality
(Figure 1E), and it decreased plasma levels of IL-1b,
TNF-a, and IL-6 (Figures 1F–1H). In comparison, inhibition
of TNF-a signaling through administration of soluble TNF-
a receptor (Etanercept) (Suffredini et al., 1995) was less ef-
ficient in reducing LPS toxicity in IkkbDmyemice, although it
completely protected IkkbF/F controls (Figure 1G). Unlike
Anakinra, Etanercept did not reduce plasma IL-1b in
IkkbDmye mice (Figure 1H), suggesting that IL-1b was the
key inflammatory mediator in LPS-challenged IkkbDmye
mice. In addition, the initial signaling by IL-1b may be re-
sponsible for the further increase in secretion of IL-1b
and other cytokines.
Because IKKb is deleted in bothmacrophages and neu-
trophils in IkkbDmye mice, we examined which cell type
contributed to increased plasma IL-1b levels after LPS ap-
plication. We used clodronate-containing liposomes (van
Rooijen et al., 1997) and Gr-1 antibody (RB6-8C5) (Vassi-
loyanakopoulos et al., 1998) to deplete macrophages and
neutrophils, respectively. Flow cytometry of splenocytes
or peritoneal exudates, as well as immunohistochemical
staining for the macrophage marker F4/80 in spleen and
liver sections, confirmed efficient depletion of macro-
phages and Kupffer cells in IkkbDmye mice and control
mice without affecting Gr-1+ cells (Figure S3). Macro-
phage depletion improved survival in LPS-treated
IkkbDmye mice (Figure 2A), and substantially decreased
plasma IL-1b and TNF-a (Figures 2B and 2C). Successful
neutrophil depletion by anti-Gr-1 administration, as con-
firmed on blood smears (data not shown), both rendered
IkkbDmye mice significantly more resistant to LPS-induced
toxicity than IkkbF/F controls (Figure 2D) and inhibited
IL-1b release (Figure 2E), whereas the effect on plasma
TNF-a was less pronounced (Figure 2F). Thus, both neu-
trophils and macrophages contribute to IL-1b release
and mortality in LPS-challenged IkkbDmye mice. Nonethe-
less, it should be recognized that the Gr-1 antibody used
may also deplete Gr-1+CD11b+F4/80+ ‘‘inflammatory
monocytes’’ that are also likely to contribute to IL-1b
release (Taylor and Gordon, 2003).ell 130, 918–931, September 7, 2007 ª2007 Elsevier Inc. 919
Figure 1. Increased Endotoxin-Induced Mortality Is Associated with Elevated Levels of Circulating IL-1b in IkkbDmye Mice
(A) Survival of IkkbF/F (black) and IkkbDmye (gray) mice (n = 4–6) after endotoxin injection (30 mg/kg, E. coli O111:B4). (B) IL-1b, (C) TNF-a, and (D) IL-6
plasma levels after LPS administration. (E and I) Survival of IkkbF/F (solid black lines) and IkkbDmye (solid gray lines) mice after LPS administration in the
presence of IL-1ra (E) and sTNFRII (I). Dashed lines represent survival without inhibitors. (F and J) IL-1b, (G) TNF-a, and (H) IL-6 plasma levels in mice
given LPS plus the indicated inhibitors. Dashed line represents respective plasma levels of IkkbDmye mice without inhibitor. Data are averages of at
least four animals per time point. Error bars = SEM.The affect of IKKb-deficient neutrophils on IL-1b release
after endotoxin challenge was further examined in another
mouse mutant, the previously characterized Mx1-Cre x
IkkbF/F mouse, called IkkbD (Ruocco et al., 2005). In these
mice induction ofMx1-Cre by systemic injection of the in-
terferon (IFN) inducer poly(I:C) (Kuhn et al., 1995) results in
IKKb deletion in IFN-responsive cells, including all myeloid
cells (Maeda et al., 2005). IkkbD mice exhibited neutro-
philia within the first 14 days after the first poly(I:C) injec-
tion, which was not only sustained, but became more
extensive over time (Figures 3A–3D). This resembles
observations made in mice transplanted with fetal liver
cells from Ikkb/ or Rela/ mice (Horwitz et al., 1997;
Senftleben et al., 2001), indicating a role for NF-kB-depen-
dent mechanisms in neutrophil homeostasis. Importantly,
LPS administration to IkkbD mice caused 100% mortality
within 24 hr (Figure 3E), and it increased plasma IL-1b
levels dramatically, with a >40-fold increase over LPS-
treated IkkbDmyemice (compare Figure 1B with Figure 3F),
which do not display neutrophilia (data not shown). Yet,
similar to IkkbDmye mice, survival of IkkbD mice was mark-
edly improved by inhibition of IL-1bwith IL-1ra (Figure S4).920 Cell 130, 918–931, September 7, 2007 ª2007 Elsevier Inc.These results demonstrate the importance of the
neutrophils’ contribution to elevated plasma-IL-1b in
endotoxin-challenged myeloid IKKb-deficient mice, and
confirm that IL-1b is responsible for increased mortality
in these animals.
Enhanced IL-1b Release by IKKb-Deficient
Macrophages and Neutrophils Is Mediated
by Distinct Mechanisms
To investigate the mechanisms underlying the unex-
pected increase in plasma IL-1b and TNF-a, we prepared
bone marrow-derived macrophages (BMDMs) from IkkbD
mice. These cells were highly compromised in LPS-
induced NF-kB activation (Figure S5) and showed de-
creased pro-IL-1b and TNF-amRNA induction (Figure 4A),
which was paralleled by reduced levels of pro-IL-1b and
pro-TNF-a, and decreased TNF-a release (Figures 4B
and 4D). However, despite reduced pro-IL-1b expression,
LPS treatment of IkkbD macrophages resulted in more
IL-1b secretion than did the same treatment of NF-kB-
competent IkkbF/F cells (Figure 4C). Immunoblot analysis
revealed that the IL-1b secreted by IkkbD macrophages
Figure 2. Depletion of either Macrophages or Neutrophils Improves Survival in IkkbDmye Mice
(A and D) Survival of IkkbF/F (black lines) and IkkbDmye (gray lines) mice depleted of macrophages (A) or neutrophils (D). Dashed lines represent survival
without depletion. (B and E) IL-1b and (C and F) TNF-a plasma levels after LPS administration in macrophage-depleted (B and C) or neutrophil-
depleted (E and F) mice. Dashed line represents respective plasma levels in IkkbDmyemicewithout depletion. Data are averages of at least four animals
per time point. Error bars = SEM.was properly processed (Figure 4D). Thus, IkkbD macro-
phages show the expected decrease in pro-IL-1b mRNA
synthesis, but due to very efficient pro-IL-1b processing,
they secrete much more IL-1b than control macrophages.
IKKb-deficient macrophages are also more susceptible
to LPS-induced apoptosis than normal cells (Park et al.,
2005). To investigate whether increased macrophage ap-
optosis, which can result in caspase-1 activation, contrib-
uted to enhanced release of IL-1b, as proposed previously
(Hogquist et al., 1991), we employed the pan-caspase in-
hibitor Z-VAD-fmk and the general serine protease inhibi-
tor TPCK, both of which inhibit apoptosis in IKKb-deficient
macrophages (Park et al., 2005). Both inhibitors were
equally or more effective than the caspase-1 inhibitor
Ac-YVAD-cmk, used as a positive control in these exper-
iments, in inhibiting IL-1b secretion (Figure 4E), suggesting
that enhanced IL-1b processing in IKKb-deficient macro-
phages is due to enhanced apoptosis and caspase-1 ac-
tivation. Indeed, IkkbDmye macrophages exhibited higher
levels of activated caspase-3 (Figure 4B) and secreted
more activated caspase-1 than control macrophages
(Figure 4F) while expressing normal amounts of intracellu-
lar pro-caspase-1 (Figure S6).
One of the NF-kB-dependent antiapoptotic genes in
macrophages is the serpin plasminogen activator inhibitor
2 (PAI-2), which is not expressed in THP1 cells, a human
myelomonocytic cell line in which LPS treatment alone
(without cotreatment with ATP) results in IL-1b secretion
(Martinon et al., 2002; Park et al., 2005). Reintroductionof PAI-2 into IkkbD macrophages inhibited LPS-induced
apoptosis, as judged by annexin V staining, and com-
pletely blocked LPS-induced IL-1b secretion (Figure 4G).
These results directly demonstrate that the product of an
NF-kB regulated gene serves as a negative regulator of
caspase-1-dependent IL-1b secretion. Recently, while
this work was under revision, Bruey et al. demonstrated
that another NF-kB-dependent antiapoptotic gene prod-
uct, Bcl-xL, is also a negative regulator of IL-1b secretion
(Bruey et al., 2007).
We next turned to neutrophils to determine whether
IL-1b processing is also enhanced in these cells in the ab-
sence of IKKb. Thioglycollate-elicited peritoneal neutro-
phils were purified and examined for IL-1b and TNF-a
expression and release. Immunoblot analysis corrobo-
rated efficient deletion of IKKb in IkkbD neutrophils and
inhibition of LPS-induced NF-kB activation (Figure S7).
To examine whether loss of IKKb affects neutrophil func-
tion, we measured chemotaxis and bactericidal activity.
Whereas chemotactic activity was increased in IkkbD neu-
trophils (Figure S7D), we could not observe any differ-
ences between the two genotypes in their capacity to kill
live E. coli within 8 hr after infection (Figure S7E). Interest-
ingly, plasma IL-1b levels were also increased in E. coli-
infected IkkbD mice (Figure S7). As in macrophages, we
found reduced LPS-induced IL-1b and TNF-a mRNA in
IkkbD neutrophils (Figure 5A). Intracellular pro-IL-1b levels
were downregulated as well (Figure 5B), though to an
even greater extent than in macrophages (Figure 4B).Cell 130, 918–931, September 7, 2007 ª2007 Elsevier Inc. 921
Figure 3. IkkbD Mice Develop Granulocytosis and Show a Massive Increase in Circulating IL-1b after Endotoxin Exposure
(A) Complete and differential blood counts and spleen weights of IkkbF/F and IkkbDmice. Data are average values for five mice of each genotype ex-
amined 2weeks after a single poly(I:C) injection. (B andC) Blood smears stained withWright-Giemsa and (D) number of CD11b+/Gr-1+ cells in spleens
of IkkbF/F and IkkbDmice analyzed 2weeks after poly(I:C) injection. (E) Survival of IkkbF/F (black) and IkkbD (gray) mice (n = 4–6) after endotoxin injection
(20mg/kg, E. coli O111:B4). (F) IL-1b and (G) TNF-a plasma levels 1, 2, and 6 hr after LPS administration. Data are averages of at least four animals per
time point. Error bars = SEM.Nonetheless, supernatants of IkkbD neutrophils con-
tained more immunoreactive IL-1b than those of IkkbF/F
cells (Figure 5C), paralleling the results in macrophages.
TNF-a secretion, however, was decreased as expected
(Figure 5D).
To examine if increased IL-1b release by IKKb-deficient
neutrophils was also associatedwith enhanced apoptosis,
we analyzed annexin V staining, which marks apoptotic
cells, of Gr-1+ neutrophils before and after ex vivo LPS
stimulation. In sharp contrast tomacrophages, the number
of apoptotic neutrophils was lower before and after LPS
stimulation (especially at earlier time points) when cells
were obtained from IkkbD mice instead of IkkbF/F mice
(Figure 5E). Likewise, no difference in caspase-3 activation
could be detected between IkkbF/F and IkkbD neutrophils
24 hr after LPS addition (Figure 5F). Thus, in neutrophils,
IKKb deficiency attenuates apoptosis and may therefore
account for the neutrophilia observed in IkkbDmice. Unlike
macrophages in which LPS-induced IL-1b secretion was
diminished in the absence of caspase-1, neutrophils
from caspase-1/mice did not exhibit reduced bioactive
IL-1b secretion after LPS stimulation (Figure 5G), as con-
firmed by an IL-1b bioassay (Figure 5H). Taken together,
these data suggest that an IKKb-regulated, caspase-
1-independent mechanism of IL-1b processing accounts
for IL-1b release by neutrophils.922 Cell 130, 918–931, September 7, 2007 ª2007 Elsevier Inc.Enhanced Serine Protease Activity
in IKKb-Deficient Neutrophils
Proteinase 3 (PR3), neutrophil elastase (NE), and cathep-
sin G (CatG) are the main serine proteases of azurophilic
granules of neutrophils (Pham, 2006), and may play
a role in IL-1b and TNF-a release (Coeshott et al., 1999).
We therefore examined whether these enzymes are acti-
vated in IKKb-deficient neutrophils and if their activation
might be linked to IL-1b processing. MeOSuc-AAPV-
pNA is a high-affinity substrate for NE and murine PR3
(Wiesner et al., 2005) that can be used to measure the
activity of NE and PR3 in mice. Hydrolysis of MeOSuc-
AAPV-pNA was markedly elevated in lysates of IkkbD
neutrophils, even without LPS stimulation (Figure 6A). To
distinguish between NE and PR3, we used recombinant
secretory leukoprotease inhibitor (SLPI), an inhibitor of
NE and CatG that does not block PR3 (Wiesner et al.,
2005). SLPI blocked MeOSuc-AAPV-pNA hydrolysis by
50% in lysates of IkkbD neutrophils, but a similar degree
of inhibition was also seen in IkkbF/F control neutrophils,
suggesting that NE activity is only partially responsible
for elevated IL-1b processing in IKKb-deficient neutro-
phils. The nonspecific serine protease inhibitor 3, 4-
dichloroisocoumarin (3, 4-DCIC) completely blocked pro-
tease activity, confirming the enzymatic specificity of the
assay results (Figure 6A). To determine whether enhanced
Figure 4. Increased IL-1b Release Correlates with Elevated Apoptosis of IKKb-Deficient Macrophages and Is Inhibited by PAI-2
(A) Relative levels of IL-1b and TNF-a mRNA after incubation of IkkbF/F (black bars) and IkkbD (gray bars) BMDM with LPS (100 ng/ml).
(B) Immunoblot analysis of intracellular pro-IL-1b, pro-TNF-a, and cleaved caspase-3 in macrophages after LPS stimulation (100 ng/ml).
(C) IL-1b levels in supernatants of IkkbF/F (black bars) and IkkbD (gray bars) macrophages after LPS stimulation.
(D) Immunoblot analysis of processed IL-1b and TNF-a in supernatants of cultured macrophages.
(E) IL-1b in supernatants of LPS-stimulated IkkbF/F (black) and IkkbD (gray) macrophages in the presence of Ac-YVAD-cmk (100 mM), Z-VAD-fmk
(10 mM), and TPCK (10 mM). Data are averages of at least three animals.
(F) Loss of IKKb activity enhances caspase-1 activation. WT or IKKb-deficient macrophages were pretreated with ML120B (30 mM) or DMSO and
either left unstimulated or incubated with LPS (100 ng/ml). After 22 hr, culture supernatants were collected and analyzed by immunoblotting for se-
cretion of activated caspase-1 (p17). The highest mobility represents uncleaved pro-caspase-1.
(G) Reconstitution of IKKb-deficient macrophages with PAI-2 blocks apoptosis and IL-1b release. Bone marrow of IkkbDmice was retrovirally trans-
duced with EGFP-PAI-2. EGFP+ cells were sorted, differentiated into macrophages, and stimulated with LPS (100 ng/ml) for 24 hr. Apoptosis was
determined by annexin V staining and IL-1b levels in supernatants were determined by ELISA.
Data are averages of at least four animals per time point. Error bars = SEM.Cell 130, 918–931, September 7, 2007 ª2007 Elsevier Inc. 923
Figure 5. Increased IL-1b Release Is Independent of Apoptosis in IKKb-Deficient Neutrophils
(A) Levels of IL-1b and TNF-a mRNA in neutrophils after LPS stimulation were examined by RNase protection.
(B) Immunoblot analysis of intracellular pro-IL-1b and pro-TNF-a in neutrophils after LPS stimulation.
(C and D) IL-1b and TNF-a secretion by LPS-stimulated neutrophils determined by ELISA.
(E) Number of annexin V+ Gr-1+ cells determined by flow cytometry.
(F) Immunoblot analysis of cleaved caspase-3 in neutrophils after LPS stimulation (100 ng/ml).
(G) IL-1b secretion by LPS-stimulated WT and caspase-1/ macrophages and neutrophils.
(H) Bioassay of supernatants of LPS-stimulated WT and caspase-1/ neutrophils determined by using EL-4 cells.
Data are averages of at least four animals per time point. Error bars = SEM.924 Cell 130, 918–931, September 7, 2007 ª2007 Elsevier Inc.
Figure 6. Elevated Serine Protease Activity in IKKb-Deficient Neutrophils Accounts for Enhanced IL-1b Secretion
(A) Hydrolysis of MeOSuc-AAPV-pNA was used to determine serine protease activity in IkkbF/F (black bars) and IkkbD (gray bars) neutrophils treated
with LPS and the protease inhibitors SLPI (1mg/ml) or 3, 4-DCIC (10 mM).
(B) PR3, serpin B1/MNEI, and PAI-2 expression in LPS-stimulated neutrophils determined by immunoblotting.
(C) Immunoblot analysis of IL-1b expression in supernatants of neutrophils 16 hr after LPS stimulation in the presence of Ac-YVAD-cmk (100 mM),
MeOSuc-AAPV-cmk (500 mM), or TPCK (10 mM).
(D and E) Immunoblot analysis of IL-1b produced in HEK293 cells after incubation with increasing amounts of purified NE (D) and PR3 (E) without or in
the presence of AAPV.
(F) Bioassay of extracts used in (D) and (E) determined by using EL-4 cells.
(G–L) Survival of IkkbF/Fmice (black lines) and IkkbDmice (gray lines) after pretreatment with the serine protease inhibitor MeOSuc-AAPV-cmk (1 mg/
mouse) (G) or Ac-YVAD-cmk (J) 1 hr before LPS application and corresponding IL-1b (H and K) and TNF-a (I and J) plasma levels. Dashed lines in (G)
and (J) represent survival without inhibitor, and in (H) and (I) and (K) and (L), they represent plasma IL-1b and plasma TNF-a levels of IkkbDmye mice
without inhibitor, respectively.
Data are averages of at least four animals per time point. Error bars = SEM.enzyme activity was due to increased expression, we ex-
amined PR3 protein levels, but found them to be only
modestly (2-fold) upregulated in IkkbD neutrophils
(Figure 6B). RNA analysis of PR3, NE, and CatG confirmed
this modest upregulation (Figure S8). Because the 2-fold
increase in PR3 expression cannot account for the 5-
fold increase in protease activity, PR3 enzymatic activityis also increased in IKKb-deficient neutrophils. To deter-
mine which serpin could be responsible for this increased
activity, we examined the RNA and protein expression of
various serpins, some of which are known to be regulated
by NF-kB. Interestingly, of these, serpin B1 (monocyte
neutrophil elastase inhibitor [MNEI]) showed an in-
creased expression in IkkbD neutrophils, suggestingCell 130, 918–931, September 7, 2007 ª2007 Elsevier Inc. 925
a compensatory mechanism. However, similarly to mac-
rophages, PAI-2 expression was absent in IkkbD neutro-
phils, suggesting its involvement in PR3 regulation.
We next determinedwhether PR3 or another serine pro-
tease is a major contributor to enhanced IL-1b processing
in IKKb-deficient neutrophils. Neutrophils were treated or
not with different protease inhibitors and stimulated with
LPS, and IL-1b in culture supernatants was assayed. Im-
munoblot analysis revealed that in IKKb-proficient neutro-
phils, themajority of secreted IL-1bwas unprocessed pro-
IL-1b, whereas in supernatants of IkkbD neutrophils, most
of the immunoreactive IL-1b was the processed form,
whose release was inhibited by the different protease in-
hibitors (Figure 6C). To confirm that NE and PR3 can pro-
cess pro-IL-1b, we produced pro-IL-1b in HEK293 cells
and incubated it with purified NE or PR3 (Figures 6D and
6E). PR3 efficiently and dose-dependently processed
pro-IL-1b to IL-1b, and was clearly more potent than NE.
Formation of mature, bioactive IL-1b was confirmed by
a bioassay (Figure 6F). Importantly, administration of
MeOSuc-AAPV-cmk completely protected IkkbD mice
from LPS-induced lethality (Figure 6G) and led to a dra-
matic decrease in plasma IL-1b and TNF-a (Figures 6H
and 6I). Administration of a1-anti-trypsin, a potent inhibitor
of extracellular, but not intracellular, NE and PR3, did not
improve survival and did not decrease IL-1b plasma levels
(data not shown). The caspase-1 inhibitor Ac-YVAD-
cmk was not as efficient in protecting IkkbD mice from
LPS-induced lethality as MeOSuc-AAPV-cmk. Although
MeOSuc-AAPV-cmkdid not affectmacrophage apoptosis
(data not shown), we cannot rule out certain off-target
effects of this inhibitor, and as discussed below, the initial
PR3-dependent (or a different protease-dependent) IL-1b
release by IKKb-deficient neutrophils may trigger cas-
pase-1-mediated IL-1b processing by IKKb-deficient
macrophages. Overall, increased intracellular serine pro-
tease activity, particularly PR3 and to a lesser extent NE,
in IKKb-deficient granulocytes can account for increased
IL-1b release by these cells.
To evaluate whether PR3 activity is regulated directly by
NF-kB rather than by other IKKb functions (Wegener et al.,
2006), we isolated neutrophils from Mx1-Cre x RelaF/F
mice, called RelaD, which produce a RelA protein that
lacks its nuclear localization signal (NLS) and part of the
transactivation domain, and are therefore functionally de-
ficient for NF-kB p65/RelA (Algu¨l et al., 2007). Like IkkbD
neutrophils, RelaD neutrophils also displayed enhanced
serine protease activity and continued to secrete IL-1b de-
spite diminished pro-IL-1b expression levels (Figure S9).
These results indicate that defective NF-kB activation
can account for increased serine protease activity and
IL-1b secretion in IKKb-deficient neutrophils.
Pharmacological IKKb Inhibition also Results
in Neutrophilia and LPS Sensitivity
In IkkbDmye and IkkbD mice, IKKb is absent in specific cell
types responsible for TNF-a and IL-1b production during
endotoxin challenge. However, NF-kB is activated nor-926 Cell 130, 918–931, September 7, 2007 ª2007 Elsevier Inc.mally in other cells (Greten et al., 2004; Maeda et al.,
2005). This situation may not fully mimic a potential thera-
peutic intervention with a systemically active inhibitor,
which is likely to target all cells. We therefore also em-
ployed a pharmacological approach using the selective
IKKb inhibitor ML120B (Nagashima et al., 2006).
ML120B effectively inhibited IKKb and NF-kB activation
inmyeloid cells (Figure S10), but its short-term administra-
tion to wild-type mice had little impact on LPS-induced
mortality (Figure 7A). Plasma IL-1b levels were increased,
whereas levels of circulating TNF-a were dramatically de-
creased (Figures 7B and 7C).
Administration of ML120B for several days leads to
granulocytosis (Nagashima et al., 2006), resembling the
phenotype of IkkbD mice. We therefore examined whether
repetitive ML120B treatment augmented LPS sensitivity.
Wild-type mice were given ML120B twice daily (300 mg/kg
each time) for 4 days and development of neutrophilia
was confirmed in blood smears (data not shown). Similar
to IkkbD mice, ML120B-treated animals were much more
susceptible to LPS-induced mortality than untreated mice
(Figure 7D). Plasma IL-1b was dramatically upregulated,
whereas the initial LPS- induced surge in plasma TNF-a
was suppressed (Figures 7E and 7F). Thus, prolonged
IKKb inhibition increases susceptibility to endotoxin-in-
duced shock andmortality by enhancing IL-1b processing.
DISCUSSION
IKKb-dependent NF-kB activation is considered to play
a major role in the transcriptional control of acute and
chronic inflammation (Bonizzi and Karin, 2004), suggest-
ing that IKKb inhibitors may be effective anti-inflammatory
drugs (Karin et al., 2004). Unexpectedly, and counterintu-
itively, inhibition of this central pathway enhances suscep-
tibility to endotoxin-induced shock and mortality by aug-
menting IL-1b processing and secretion. These findings
stand in sharp contrast to the marked ability of IKKb inhi-
bition to prevent TNF-a expression and release, an end-
point that raised enthusiasm for targeting IKKb in chronic
inflammatory diseases such as rheumatoid arthritis and
inflammation-induced bone loss (McIntyre et al., 2003;
Ruocco et al., 2005). Thus, in addition to revealing an un-
anticipated role for IKKb-dependent NF-kB activation as
a negative regulator of pro-IL-1b processing, our results
raise serious concerns about the long-term impact of
IKKb inhibition. However, it is possible that enhanced IL-
1b processingmay occur only upon acute septic infection,
where, as discussed below, it is likely to play a protective
role, and we suggest ways to avoid such complications. It
should also be noted that partial and transient inhibition of
IKKb does not seem to be as problematic.
Prolonged inhibition of NF-kB, however, leads to en-
hanced processing of pro-IL-1b, despite a profound
transcriptional inhibition of NF-kB-dependent gene ex-
pression, including inhibition of IL-1b gene transcription.
Whereas NF-kB positively regulates a major transcrip-
tional control point in inflammation and innate immunity
Figure 7. Prolonged Pharmacological Inhibition of IKKb Enhances IL-1b Secretion and Endotoxic Shock
(A–C) Survival and corresponding IL-1b and TNF-a plasma levels of LPS-challenged WT mice given 300 mg/kg of the IKKb inhibitor ML120B by oral
gavage 1 hr prior to LPS administration (30 mg/kg). (D) Survival and corresponding IL-1b (E) and TNF-a (F) plasma levels in WT mice given 300 mg/kg
ML120B by oral gavage twice daily for 4 days before LPS challenge. (G) Schematic representation of the proposed dual role of IKKb-dependent
NF-kB activation in regulation of IL-1b secretion bymacrophages and neutrophils: in neutrophils, which appear to be a rapid, but minor (albeit critical),
source of IL-1b, IKKb-driven NF-kB positively regulates the transcription of pro-IL-1bmRNA and serine protease inhibitor genes whose products in-
hibit the activity of PR3, which can process pro-IL-1b. Secretion of biologically active IL-1b by neutrophils acts together with LPS to augment IL-1b
secretion by macrophages, which represent the major source of this cytokine. In the macrophage, NF-kB controls pro-IL-1bmRNA synthesis as well
as the expression of genes such as PAI-2, Bcl-xL, and ICEBERG, whose products inhibit caspase-1 activation. Data are averages of at least four
animals per time point. Error bars = SEM.(Ghosh and Karin, 2002), the regulation of pro-IL-1b (and
pro-IL-18) processing acts as a control of innate immunity
and inflammation at the posttranscriptional level (Marti-
non and Tschopp, 2004). Regulation of IL-1b (and IL-18)
secretion differs from that of most other cytokines, as
IL-1b does not contain a signal peptide and its productionCand release depend on transcriptional and posttranscrip-
tional processes (Dinarello, 2005; Martinon and Tschopp,
2004; Ogura et al., 2006). The majority of IL-1b induced
upon endotoxin challenge in an NF-kB-dependent man-
ner remains in the cell as pro-IL-1b, and the picogram
amounts of IL-1b released by myeloid cells activated byell 130, 918–931, September 7, 2007 ª2007 Elsevier Inc. 927
LPS alone are small compared with nanogram amounts of
TNF-a or IL-6. Whereas NF-kB is the main transcription
factor controlling IL-1b gene induction, caspase-1 is the
major protease required for pro-IL-1b processing, espe-
cially in macrophages (Kuida et al., 1995; Li et al., 1995).
Akin to NF-kB, whose activation depends on the signal-
responsive IKK complex (Ghosh and Karin, 2002), also
termed the signalsome (Mercurio et al., 1997), caspase-1
is regulated by the inflammasome, a group of related
protein complexes which can respond to different ligands
(Martinon and Tschopp, 2004; Ogura et al., 2006). How-
ever, several other proteases, including NE, PR3, CatG,
chymase, and chymotrypsin, as well as certain matrix
metalloproteinases, were shown to be capable of cleav-
ing pro-IL-1b at critical sites involved in generation and
secretion of the bioactive molecule (Black et al., 1988;
Dinarello et al., 1986; Hazuda et al., 1990; Irmler et al.,
1995; Mizutani et al., 1991). It was speculated that these
enzymes, once secreted, cleave pro-IL-1b extracellularly,
thereby amplifying the inflammatory reaction (Fantuzzi
et al., 1997). Our results strongly suggest that although
the majority of IL-1b in mice lacking NF-kB activity in my-
eloid cells is derived from excessive caspase-1 activation
in macrophages, neutrophils (and inflammatory mono-
cytes) also play an important role in excessive IL-1b
release, perhaps by augmenting its release from macro-
phages (Figure 7G). In neutrophils lacking IKKb, IL-1b is
secreted through a caspase-1-independent mechanism.
In these cells intracellular serine proteases, especially
PR3, are involved in IL-1b processing and secretion. In
support of this, pretreatment of IkkbD mice with purified
a1-anti-trypsin, which inhibits extracellular serine prote-
ases (Liu et al., 2000), did not reduce IL-1b secretion,
but a cell-permeable peptide specifically blocking NE
and PR3 reduced IL-1b production substantially and
protected IkkbD mice from endotoxin-induced death.
Nonetheless, we cannot rule out off-target effects of this
particular inhibitor, MeOSuc-AAPV-cmk, and a caspase-1
inhibitor, Ac-YVAD-cmk, also blocked excessive IL-1b
secretion.
We tried to determine which cell type is responsible for
enhanced IL-1b release after IKKb or NF-kB depletion or
inhibition in myeloid cells. We found that in LPS-
challenged IkkbDmye mice, depletion of either neutrophils
(and inflammatory monocytes) or macrophages was pro-
tective, suggesting critical involvement of all these cell
types. Similar results were observed with the use of prote-
ase inhibitors. Both the caspase-1 inhibitor Ac-YVAD-cmk
and the PR3 inhibitor MeOSuc-AAPV-cmk led to an al-
most complete inhibition of IL-1b secretion in IkkbD mice
(Figures 6H and 6K). However, caspase-1 activity is re-
quired for IL-1b processing and secretion only in macro-
phages. In vitro, IKKb-deficient macrophages secrete
muchmore (7- to 10-fold) IL-1b per cell cell after LPS stim-
ulation than IKKb-deficient neutrophils under the same
conditions. Furthermore, in vitro treatment with an IKKb in-
hibitor readily augments caspase-1 activation and IL-1b
secretion by LPS-treated macrophages (Figure 4F), and928 Cell 130, 918–931, September 7, 2007 ª2007 Elsevier Inc.caspase-1 inhibition prevents IL-1b secretion. These re-
sults suggest that the major IL-1b producers under these
conditions are the macrophages; yet, depletion of neutro-
phils (and inflammatory monocytes) via a strategy that
leaves the macrophages intact also results in substantial
inhibition of massive IL-1b secretion. To reconcile these
results, we suggest that the initial and more rapid release
of IL-1b by IKKb-deficient neutrophils may augment the
delayed and more substantial IL-1b secretion by IKKb-
deficient macrophages (Figure 7G). In support of this hy-
pothesis, administration of an inhibitor of IL-1b signaling
(IL-1ra) also inhibits IL-1b secretion (Figure 1F).
It was previously found that caspase-1 activation is en-
hanced by macrophage apoptosis (Hogquist et al., 1991).
Macrophage apoptosis is increased in the absence of
NF-kB due to defective expression of A1/Bfl-1 and PAI-2,
which are encoded by NF-kB target genes (Park et al.,
2005). It is well established that in addition to these genes,
NF-kB controls expression of genes that encode direct
caspase inhibitors (Karin and Lin, 2002). Such molecules
may inhibit caspase-1 activation both directly and indi-
rectly by suppressing macrophage apoptosis. In human
cells, NF-kB may also regulate expression of ICEBERG,
which appears to be a dedicated inhibitor of inflamma-
some activation (Humke et al., 2000). In addition, while
this manuscript was under revision, it was shown that
Bcl-xL, which is encoded by an NF-kB target gene, and
its relative Bcl-2 directly inhibit caspase-1 activation by
NALP1 (Bruey et al., 2007). In neutrophils, production of
IL-1b depends not on caspase-1 but mainly on serine pro-
teases, whose activity is also negatively regulated by NF-
kB. It was documented that expression of several serine
protease inhibitors (serpins), including PAI-2, MNEI, and
proteinase inhibitor 9 (PI-9) is transcriptionally activated
by NF-kB (Kannan-Thulasiraman and Shapiro, 2002;
Park et al., 2005; Zeng and Remold-O’Donnell, 2000). Of
these, PAI-2 expression is dramatically reduced in IKKb-
deficient neutrophils and macrophages and restoration
of PAI-2 expression in IKKb-deficient macrophages in-
hibits LPS-induced IL-1b secretion. However, the direct
target for PAI-2 that is involved in control of IL-1b process-
ing is currently unknown.
Repetitive administration of a specific IKKb inhibitor
mimicked the effect of myeloid IKKb deletion despite effi-
cient inhibition of NF-kB-mediated gene induction, includ-
ing pro-TNF-a and pro-IL-1b synthesis. We suggest that
the high stability of pro-IL-1bmay account for its accumu-
lation over time, even when pro-IL-1b mRNA synthesis is
inhibited. It is also plausible that the translational effi-
ciency of pro-IL-1b mRNA may be increased once its
levels drop below a certain threshold. In vitro, treatment
of macrophages with an IKKb inhibitor strongly augments
LPS-induced caspase-1 activation and obliterates the
need for a second signal, such as high concentrations of
ATP.
Collectively, our results illustrate that, quite unexpect-
edly, IKKb and NF-kB are also involved in negative regula-
tion of inflammasome activation. It is well established that
inflammation is a potentially dangerous, but protective, re-
sponse that is controlled by numerous negative feedback
mechanisms (Cohen, 2002; Karin et al., 2006). While many
of these negative regulators act transcriptionally by target-
ing NF-kB or IKK, our work reveals additional negative
regulatory mechanisms that act posttranscriptionally
through inhibition of pro-IL-1b processing. However, it is
also possible that themajor goal of the negative regulatory
mechanisms we unraveled is to augment host defense
rather than inhibit inflammation. Since certain highly viru-
lent pathogens have evolved the ability to inhibit NF-kB
activation and thereby evade NF-kB-dependent innate
immunity (Orth et al., 2000), the augmented secretion of
IL-1b by NF-kB-deficient myeloid cells may provide
a compensatory mechanism that allows activation of an
additional, NF-kB-independent, host defense response.
Undoubtedly, the mechanistic details of IL-1b produc-
tion and its regulation by NF-kB also need to be assessed
in normal human macrophages and neutrophils. Until
then, our results raise serious concerns about possible
complications associated with long-term inhibition of
NF-kB. Although pharmacological inhibition is unlikely to
be as complete as genetic disruption, it may cause loss
of innate immunity and augment acute inflammation asso-
ciated with septic infections.
EXPERIMENTAL PROCEDURES
Mice
IkkbDmye, IkkbD, and IkkbF/F mice have been described (Greten et al.,
2004; Ruocco et al., 2005). To delete IKKb in IkkbD mice, 250 mg
poly(I:C) (Sigma) was injected i.p. 2 weeks before LPS administration
or isolation of myeloid cells. Generation of RelaF/F mice is described
elsewhere (Algu¨l et al., 2007). Four to six mice of each genotype
were i.p. injected with LPS (E. coli O111:B4, Sigma), CpG-DNA
(ODN1668), or E. coli (serotype O111:K58), or injected i.v. with
L. monocytogenes wild-type (10403S). Etanercept (Enbrel, Amgen),
Ac-YVAD-cmk (Calbiochem), and MeOSuc-AAPV-cmk (Calbiochem)
were given i.p. 1 hr before LPS administration. Anakinra (Kineret, Am-
gen) was injected subcutaneously every 4 hr over a period of 12 hr.
ML120B (Nagashima et al., 2006) was given by oral gavage either
once before LPS or twice daily over 4 days. Clodronate-liposomes
and RB6-8C5 were applied i.p. 24 hr before LPS. Liposome-encapsu-
lated clodronate (a kind gift of Roche Diagnostics GmbH, Mannheim,
Germany) was prepared as previously described (Van Rooijen and
Sanders, 1994).
Isolation of Macrophages and Neutrophils
BMDMs were generated as described (Greten et al., 2004). To isolate
neutrophils, mice were i.p. injected with 1 ml of 3% thioglycollate
(DIFCO) and peritoneal cells were flushed out 3–5 hr later. After block-
ing Fc-receptors with anti-CD16/32 (Becton & Dickinson), cells were
incubated with PE-labeled Gr-1 antibody (Becton & Dickinson) and
magnetically separated using anti-PE beads according to the manu-
facturer’s (Miltenyi Biotec) instructions. Retroviral reconstitution was
performed essentially as described (Miething et al., 2007). Bone mar-
rowwas transduced with EGFP-PAI-2 retrovirus and EGFP+ cells were
sorted by flow cytometry. EGFP+ and EGFP cells were differentiated
into macrophages and stimulated with LPS.
Protein and RNA Analysis
IL-1b and TNF-a in plasma and cell supernatants weremeasured using
the DuoSet ELISA systems (R&D Systems) according to manufac-turer’s instructions. RNA was extracted using Trizol (Invitrogen).
RNase Protection Assay (RPA) was performed as described (Park
et al., 2005). cDNA synthesis, real-time PCR, immunoblot, and Electro-
phoretic Mobility Shift Assay (EMSA) were as described (Greten et al.,
2004). Primer sequences are available upon request. Antibodies rec-
ognizing IL-1b, TNF-a (R&D Systems), IL-1b (for Immunoprecipitation
[IP]) and cleaved caspase-3 (Becton & Dickinson), b-actin (Sigma),
IKKb (UBI), RelA, IkBa, and PR3 (Santa Cruz) were purchased from
the indicated suppliers.
Protease Activity Determination and Inhibition
Cell pellets were lysed and hydrolysis of MeOSuc-AAPV-pNA (Calbio-
chem) was determined in 0.05MNaH2PO4, 0.1MNaCl, 0.005%Triton
X-100, and 5% DMSO at 405 nm. For inhibition experiments rhSLPI
(R&D Systems) and 3, 4-DCIC (Calbiochem) were used.
In Vitro Processing of pro-IL-1b and IL-1b Bioassay
HEK293 cells were transfected with pro-IL-1b expression plasmid and
cells were lysed after 24 hr. Lysates were incubated with purified NE
and PR3 (Athens Research & Technology) for 30 min. IL-1b bioassay
was performed using EL-4 cells, which were stimulated for 24 hr.
IL-2 release by EL-4 cells was measured by an ELISA (eBioscience)
according to manufacturer’s instructions.
Chemotaxis Assay
Neutrophils (13 106) were seeded in transwell plates and incubated in
the presence of 10 mM fMLP in the lower chamber for 60 min, after
which cells in the lower chamber were counted.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.cell.com/cgi/content/full/130/5/918/DC1/.
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